• Explore /
  • Poster
  • / Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.

Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.

Abstract Poster

Authors

Anna Maria Di Giacomo

Anna Maria Di Giacomo

Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy

Anna Maria Di Giacomo , Alessia Covre , Francesca Finotello , Dietmar Rieder , Luca Sigalotti , Diana Giannarelli , Florent Petitprez , Laetitia Lacroix , Ornella Cutaia , Carolina Fazio , Sandra Coral , Andrea Anichini , Christoph Bock , James N. Lowder , Mohammad Azab , Wolf-Herman Fridman , Catherine Sautes-Fridman , Zlatko Trajanoski , Michele Maio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Conduct of Clinical Research

Clinical Trial Registration Number

NCT02608437

Citation

J Clin Oncol 37, 2019 (suppl; abstr 2549)

DOI

10.1200/JCO.2019.37.15_suppl.2549

Abstract #

2549

Poster Bd #

193

Abstract Disclosures

Similar Posters

First Author: Anna Maria Di Giacomo

First Author: Michael Andrew Postow

First Author: Paola Queirolo

First Author: James M. G. Larkin